Profiling the bronchodilator effects of the novel ultra-long-acting β-agonist indacaterol against established treatments in chronic obstructive pulmonary disease
Indacaterol is a novel, inhaled, ultra-long-acting β 2 -agonist providing 24-h bronchodilation with once-daily (od) dosing for maintenance use in patients with chronic obstructive pulmonary disease (COPD). This article reviews the bronchodilator properties of indacaterol compared with other treatmen...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2011-10-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/1753465811410100 |